A Study of KC1036 in Patients with Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Konruns Pharmaceutical Co., Ltd.
About this trial
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed recurrent or metastatic solid tumors;
At least one measurable lesion (by RECIST 1.1);
Eastern Cooperative Oncology Group performance status score of 0 or 1;
Life expectancy > 12 weeks;
Disqualifiers
Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks;
Other kinds of malignancies;
Hematologic, renal, and hepatic function abnormities;
Risk of bleeding;
Trial design
Treatments tested in this trial
- KC1036
Treatment groups
207 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov